Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephradine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC15A1 | P46059 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephradine SCHEMBL11236409 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL11236414 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL16072830 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL3244 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL20969062 | 1.00 | MAPT (1.00) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL11209915 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL719332 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL956675 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL3128777 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 | |
| Cephradine SCHEMBL28758599 | 0.99 | MAPT (0.98) | MAPTKMT2AHSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176773-A1 | Non-Peptidic Inhibitors of AKAP/PKA Interaction | PRKCH, AIP, PRKCE | MAPT 3655/4885KMT2A 2487/4885HSD17B10 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.